Seres Therapeutics

Company snapshot

Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboratio

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 36 US patent(s) indexed to this assignee profile.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Seres Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Seres Therapeutics.

1. Jun 8, 2026 Clinical update

   Vancomycin Pre-Treatment — Phase 2

2. Jun 8, 2026 Clinical update

   Vancomycin Pre-Treatment — Phase 1

3. Jun 5, 2026 Clinical update

   SER-262 — Phase 1

4. Jun 5, 2026 Clinical update

   SER-109 — Phase 3

5. Jun 5, 2026 Clinical update

   SER-109 — Phase 2

View all clinical trial activity →

• What is Seres Therapeutics?

  Seres Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker MCRB. Primary therapeutic focus areas include Clostridium Difficile Infection, Ulcerative Colitis, Metastatic Melanoma, Clostridioides Difficile Infection, Clostridium Diff

• Is Seres Therapeutics publicly traded?

  Yes. Seres Therapeutics is listed with ticker MCRB on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Seres Therapeutics develop or market?

  We link 7 drug profile(s) where Seres Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/seres-therapeutics#company-drugs.

• What are the latest developments for Seres Therapeutics?

  In the last 12 months our linked public records show 8 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Seres Therapeutics focus on?

  Seres Therapeutics focuses on Clostridium Difficile Infection, Ulcerative Colitis, Metastatic Melanoma based on our analysis of their pipeline programs and drug development activities.